7 unknown. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Unknown 7 |
Follow Thymoma: new trials by email Literature Review of Thymoma trials Research Report on Thymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train. NAB-Paclitaxel plus Cisplatin, Cisplatin plus Epirubicin plus Cyclophosphamide - Histological or Cytological Confirmed Stage Ⅲ and Ⅳa Thymoma | Phase 2 | Unknown | Peng Liu | 50 | 2023-04-30 | 2023-04-18 |
| Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) Ramucirumab - Thymic Carcinoma, Thymoma | Phase 2 | Unknown | Claudia Proto | 60 | 2018-11-01 | 2024-05-29 |
| Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor Thymosin a1, hypofractionated radiotherapy, concurrent chemoradiotherapy - Thymoma and Thymic Carcinoma | Phase 2 | Unknown | Sun Yat-sen University | 57 | 2018-08-13 | 2021-12-10 |
| Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma Selinexor - Thymoma, Advanced Thymic Epithelial Tumour | Phase 2 | Unknown | Morten Mau-Soerensen | 25 | 2017-10-12 | 2018-03-15 |
| Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Sunitinib - Type B3 Thymoma, Thymic Carcinoma | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 56 | 2017-03-02 | 2021-06-09 |
| Abscopal Effect of Radiotherapy in Combination With rhGM-CSF for Advanced Thymic Epithelial Tumours Radiotherapy Combined with GM-CSF - Thymoma | Phase 2 | Unknown | Shanghai Cancer Hospital, China | 60 | 2016-01-01 | 2022-06-07 |
| Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Pembrolizumab, Epacadostat - Thymic Carcinoma, Thymus Neoplasms | Phase 2 | Unknown | Georgetown University | 45 | 2015-03-01 | 2019-12-13 |
Neoplasm Metastasis (1) · Thymus Neoplasms (1)
Hemic and Lymphatic Diseases (7) · Lymphatic Diseases (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms by Site (7) · Neoplasms, Complex and Mixed (7) · Thoracic Neoplasms (7) · Thymus Neoplasms (6) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
130-nm albumin-bound paclitaxel (1) · Carboplatin (1) · Chemoradiotherapy (1) · Cisplatin (1) · Cyclophosphamide (1) · Epirubicin (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Paclitaxel (1) · Radiation Dose Hypofractionation (1) · Ramucirumab (1) · Sunitinib (1) · epacadostat (1) · pembrolizumab (1) · selinexor (1)
Claudia Proto (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Georgetown University (1) · Morten Mau-Soerensen (1) · Peng Liu (1) · Shanghai Cancer Hospital, China (1) · Sun Yat-sen University (1)
China (3) · Italy (2) · Denmark (1) · France (1) · United States (1)
Giuseppe Giaccone, MD PhD (1) · Hui Liu, Professor (1) · Marina Chiara Garassino, MD (1) · Marina Garassino, MD (1) · Morten Mau-Soerensen, MD, PhD (1)
PMID 10555755, PMID 11123390, PMID 12712448, PMID 14963856, PMID 15201427, PMID 15725919, PMID 17570676, PMID 18268188, PMID 19220526, PMID 19461405, PMID 21502559, PMID 25146529, PMID 25202099, PMID 25396308, PMID 25403584, PMID 25411417, PMID 27844328, PMID 28759346, PMID 29395863, PMID 34622229, PMID 8637524
2017 (1)